SG11201507973TA - Neuroprotective effect of carotenoids in brain - Google Patents

Neuroprotective effect of carotenoids in brain

Info

Publication number
SG11201507973TA
SG11201507973TA SG11201507973TA SG11201507973TA SG11201507973TA SG 11201507973T A SG11201507973T A SG 11201507973TA SG 11201507973T A SG11201507973T A SG 11201507973TA SG 11201507973T A SG11201507973T A SG 11201507973TA SG 11201507973T A SG11201507973T A SG 11201507973TA
Authority
SG
Singapore
Prior art keywords
carotenoids
brain
neuroprotective effect
neuroprotective
effect
Prior art date
Application number
SG11201507973TA
Other languages
English (en)
Inventor
Jayant Deshpande
J Shankaranarayanan
Original Assignee
Omniactive Health Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omniactive Health Technologies Ltd filed Critical Omniactive Health Technologies Ltd
Publication of SG11201507973TA publication Critical patent/SG11201507973TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
SG11201507973TA 2013-03-28 2014-03-28 Neuroprotective effect of carotenoids in brain SG11201507973TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/000447 WO2014155189A1 (fr) 2013-03-28 2014-03-28 Effet neuroprotecteur des caroténoïdes dans le cerveau
IN1208MU2013 IN2013MU01208A (fr) 2013-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
SG11201507973TA true SG11201507973TA (en) 2015-10-29

Family

ID=50685962

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507973TA SG11201507973TA (en) 2013-03-28 2014-03-28 Neuroprotective effect of carotenoids in brain

Country Status (12)

Country Link
US (1) US9849096B2 (fr)
EP (1) EP2978418A1 (fr)
JP (1) JP2016520540A (fr)
CN (1) CN105120853A (fr)
AU (1) AU2014242655A1 (fr)
CA (1) CA2907886A1 (fr)
HK (1) HK1211836A1 (fr)
IN (1) IN2013MU01208A (fr)
MX (1) MX2015013624A (fr)
PH (1) PH12015502238A1 (fr)
SG (1) SG11201507973TA (fr)
WO (1) WO2014155189A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145389A2 (fr) * 2014-03-28 2015-10-01 Omniactive Health Technologies Limited Effet de nutriments lipophiles sur des maladies des yeux liées au diabète
EP3265068A4 (fr) 2015-03-02 2018-10-31 OmniActive Health Technologies Limited Procédé de protection et d'amélioration de la santé du foie au moyen de compositions de méso-zéaxanthine
US10583095B2 (en) 2015-03-02 2020-03-10 Omniactive Health Technologies Limited Method for stress management and overall health status improvement and compositions used therein
US20190314442A1 (en) * 2016-02-22 2019-10-17 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases
EP3632418A4 (fr) * 2017-06-01 2021-02-24 Santen Pharmaceutical Co., Ltd. Composition destinée à la prévention et/ou à l'amélioration de dysfonctionnements cérébraux, contenant de la lutéine ou un sel de cette dernière et produit transformé issu d'une plante appartenant au genret
GB201720119D0 (en) * 2017-12-04 2018-01-17 Howard Foundation Holdings Ltd Prevention and/or treatment of neurodegenerative disease
GB201801985D0 (en) * 2018-02-07 2018-03-28 Ip Science Ltd Formulation of carotenoids
CA3095341A1 (fr) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Composition de dose fractionnee de levodopa et utilisation
SG10201900604TA (en) * 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Pre-natal beta-cryptoxanthin benefits children
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
FR3117339A1 (fr) 2020-12-16 2022-06-17 Naos Institute Of Life Science Utilisation des bactériorubérines et leurs dérivés glycosylés pour prévenir et traiter les maladies impliquant une dérégulation de l’agrégation des protéines, comme les maladies neurodégénératives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
DE19609477A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
US7081478B2 (en) 2001-06-29 2006-07-25 Chrysantis, Inc. Mixed zeaxanthin ester concentrate and uses thereof
US20060205826A1 (en) * 2005-03-09 2006-09-14 Romero Francisco J Method of using carotenoids in the prevention of cognitive decline and for other neuroprotection functions
US20070238793A1 (en) 2005-12-07 2007-10-11 Lockwood Samuel F Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
WO2008099469A1 (fr) 2007-02-14 2008-08-21 Tohoku University Composition et procédé pour supprimer la péroxydation des lipides dans les érythrocytes
PT2473065E (pt) * 2009-09-02 2016-06-03 Omniactive Health Tech Ltd Uma composição de xantofila contendo pigmentos maculares e um processo para a sua preparação
CN102210662A (zh) 2010-04-06 2011-10-12 北京联合大学应用文理学院 叶黄素在制备防治脑血管疾病药物中的应用

Also Published As

Publication number Publication date
US9849096B2 (en) 2017-12-26
IN2013MU01208A (fr) 2015-07-03
WO2014155189A1 (fr) 2014-10-02
EP2978418A1 (fr) 2016-02-03
US20160051490A1 (en) 2016-02-25
AU2014242655A1 (en) 2015-10-22
CA2907886A1 (fr) 2014-10-02
JP2016520540A (ja) 2016-07-14
CN105120853A (zh) 2015-12-02
HK1211836A1 (en) 2016-06-03
PH12015502238A1 (en) 2016-02-01
MX2015013624A (es) 2016-06-10

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
GB2530455B (en) Methods of bleaching hair
HK1211836A1 (en) Neuroprotective effect of carotenoids in brain
HK1213818A1 (zh) 依帕列淨的治療用途
PT2941163T (pt) Limpador de pele
GB201317889D0 (en) Product and use
IL286759A (en) Therapeutic methods and preparations
EP2968474A4 (fr) Compositions pour la peau et utilisations
LT2981271T (lt) Empagliflozino terapinis panaudojimas
GB2540853B (en) Beauty product displays
GB201301639D0 (en) Product and process
HK1224307A1 (zh) 原毒素- 變體及其使用方法
EP3015100A4 (fr) Produit cosmétique
HK1219294A1 (zh) 用於減少皮膚色素沉着的組合物和方法
HK1188366A2 (en) One type of massager
GB201412374D0 (en) Articl of headgear
GB201304585D0 (en) Methods and product
GB201301834D0 (en) Hair nutrition
GB201319255D0 (en) Therapeutic compositions and methods
GB201309328D0 (en) Product and use thereof
GB201311054D0 (en) Beady eyes